At this time, it is not entirely clear what to expect from an overdose with vemurafenib. It is important to seek immediate medical attention if you or someone else may have overdosed on this or any other medication.
If you forget a dose of vemurafenib, simply take the missed dose as soon as you remember, unless it is less than four hours until your next scheduled dose. In this case, skip the missed dose, and continue with your regular schedule. Do not take two doses of this medication at the same time to make up for a missed dose.
How Does This Medicine Work?
Vemurafenib is approved for use in people who have an abnormal gene known as the BRAF gene. The BRAF protein helps regulate cell growth. When the BRAF gene is abnormal, the BRAF protein is constantly turned on, causing an abnormal growth of cells, which leads to melanoma.
Vemurafenib works by blocking the action of the BRAF protein, and thus preventing abnormal cell growth. By blocking abnormal cell growth, vemurafenib can slow down the progression of melanoma.
Vemurafenib has been shown to improve survival time and delay progression of advanced melanoma in people who have not already received treatment. Everyone in the clinical study had a mutation in the BRAF gene, which is associated with melanoma.
In the study, people given vemurafenib had a progression-free survival (which is the amount of time after treatment starts that the cancer does not get worse) of about 5.3 months, compared to 1.6 months in people given a different cancer medication.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc.;2014 March.
U.S. Food and Drug Administration. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer (8/17/2011). FDA Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm. Accessed November 1, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed November 1, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click